← Back to Clinical Trials
Recruiting NCT06337123

NCT06337123 Physica TT Tibial Plate Follow up Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06337123
Status Recruiting
Phase
Sponsor Limacorporate S.p.a
Condition Knee Arthropathy
Study Type OBSERVATIONAL
Enrollment 130 participants
Start Date 2025-04-15
Primary Completion 2029-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Device: Physica TT TIbial Plate and Physica Porous KRDevice: Physica TT TIbial Plate and Physica Porous PS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 130 participants in total. It began in 2025-04-15 with a primary completion date of 2029-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical study aims at evaluating clinical, radiographic, patient-reported outcomes of total knee arthroplasty with Physica TT Tibial Plate in combination with Physica Porous KR or Physica Porous PS up to 2 years after surgery, in order to assess the performance of the devices. Furthermore, ithe objective is to collect short-term survivorship of the implant and the incidence of early complications.

Eligibility Criteria

Inclusion Criteria: 1. Male or female of any race requiring a total knee replacement (TKR) and suitable for receiving Physica Porous KR or Physica Porous PS femoral component in combination with Physica TT Tibial Plate. 2. Age ≥ 18 years old. 3. Candidate for primary total knee replacement when clinical indications based on physical examination and medical history include one or more of the following conditions: 1. Non-inflammatory degenerative joint disease like knee osteoarthritis, post traumatic knee arthritis 2. Inflammatory degenerative joint disease like rheumatoid arthritis 3. Any other medical reason for which the investigator deems the subject as a possible candidate for total knee replacement. 4. Patient has well-preserved and well-functioning collateral ligaments and one of the following conditions: 1. Absent or not-functioning posterior cruciate ligament and severe antero-posterior instability of the knee joint (for Physica Porous PS) 2. Undamaged and functional posterior cruciate ligament (for Physica Porous KR) 5. Patient is able to understand the conditions of the study, to comply with the prescribed rehabilitation as well as willing to perform all scheduled follow-up visits. 6. Patient signed the study-specific informed consent form approved by the ethics committee before study activities Exclusion Criteria: 1. Severe instability of the knee joint secondary to the absence of collateral ligament integrity and/or function. Only for Physica Porous KR: important joint instability and deficiency of posterior cruciate ligament. 2. Any active or suspected infection (local or systemic) or previous history of infection that may affect the prosthetic joint. 3. Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy. 4. Significant bone loss on femoral or tibial joint side. 5. Affected by malignant cancer with life expectancy less than 2 years or where cancer treatment might affect the normal postoperative course. 6. Known incompatibility or allergy to the product materials, and/or metal hypersensitivity to implant materials. 7. Septicaemia. 8. Persistent acute or chronic osteomyelitis. 9. Open epiphyses (immature patient with active bone growth). 10. Necrotic bone 11. Arterial vascular insufficiency or nerve diseases of the lower limbs severe enough to interfere with the study evaluation. 12. Compromised bone stock due to disease, infection or prior implantation that cannot provide adequate support and/or fixation to the prosthesis. 13. Systemic or metabolic disorders leading to progressive bone deterioration, which may impair fixation and stability of the implant. 14. Any concomitant disease and dependency that might affect the performance of the implanted prosthesis. 15. Any clinically major pathology based on clinical medical history or any medical intervention or reason that the Investigator feels may affect the study evaluation. 16. Neurological or musculoskeletal disorder or disease that may adversely affect gait, functional recovery and evaluation. 17. Neuromuscular or neurosensory deficit that would hamper the performance assessment of the device. 18. Any psychiatric illness that would prevent comprehension of the details and nature of the study. 19. Simultaneously taking part in another surgical intervention study or pain management study that may affect with clinical study outcomes. 20. Female patient who is pregnant, nursing, or planning a pregnancy. 21. Important osteoporosis, haemophilic disease. 22. Internistic problems with high risk for surgery.

Contact & Investigator

Central Contact

Domizia Baldassi

✉ domizia.baldassi@enovis.com

📞 +39 3357492586

Principal Investigator

Alessandro Tripodo

PRINCIPAL INVESTIGATOR

Casa di Cura San Camillo Hospital

Frequently Asked Questions

Who can join the NCT06337123 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Knee Arthropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06337123 currently recruiting?

Yes, NCT06337123 is actively recruiting participants. Contact the research team at domizia.baldassi@enovis.com for enrollment information.

Where is the NCT06337123 trial being conducted?

This trial is being conducted at Forte dei Marmi, Italy, Messina, Italy, Perugia, Italy.

Who is sponsoring the NCT06337123 clinical trial?

NCT06337123 is sponsored by Limacorporate S.p.a. The principal investigator is Alessandro Tripodo at Casa di Cura San Camillo Hospital. The trial plans to enroll 130 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology